Merck & co. , inc.
MRK 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，不過公司股利評分優異，若想穩定收息，仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作
MRK 近期報酬表現
0.37%
Merck & co. , inc.
6.23%
同產業平均
1.02%
S&P500
與 MRK 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
AZN | Astrazeneca plc | 4 分 | 5 分 | 4 分 | 2 分 | 5 分 | |
JNJ | Johnson & johnson | 2 分 | 2 分 | 1 分 | 3 分 | 5 分 | |
GSK | Gsk plc | 3 分 | 5 分 | 3 分 | 2 分 | 5 分 | |
LLY | Eli lilly and company | 4 分 | 5 分 | 2 分 | 3 分 | 5 分 | |
ABBV | Abbvie inc | 4 分 | 2 分 | 1 分 | 3 分 | 5 分 |
- AZN Astrazeneca plc價值 4 分趨勢 5 分波段 4 分籌碼 2 分股利 5 分查看更多
MRK 公司資訊
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company's lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.